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Abstract
Background: This study aimed to provide UK data describing the incidence of patent ductus arteriosus (PDA)
surgery in the neonatal population, including: pre-ligation management, and outcomes until discharge. We used
British Paediatric Surveillance Unit (BPSU) methodology; collecting data via questionnaires for preterm neonates
undergoing PDA ligation (PDAL) between 1st Sept 2012 – 30th Sept 2013. Infants born less than 37 weeks
gestation, who underwent PDAL prior to discharge home, with no other structural cardiac abnormality, were
included. Information collected included: patient demographics, pre and post-operative clinical characteristics, pre-
operative medical management, post-operative complications and outcome.
Results: Over the study, 263 infants underwent PDAL an incidence of 3.07 per 10,000 live births. 88% were born
extremely preterm (< 28 weeks) and 60% were male. The commonest reasons for ligation were inability to wean
respiratory support (83.7%) and haemodynamically significant PDA (87.8%). Pre-operatively 65.7% received medical
therapy. Surgery was performed at a median age of 33 days (range 9-260, IQR 24-48); the corrected age was less
than 31 + 6 week in 50.6% babies at PDAL. Most, (90%), of procedures were open ligation; only 9 (3.4%) were
catheter occlusions (PDACO). 20.5% of patients had post-operative complications. The 30-day mortality was 3%,
with 93.5% surviving to hospital discharge.
Conclusion: This study showed there was little consensus over medical and surgical management of the PDA or
timing of surgery.
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Background
The patent ductus arteriosus (PDA) remains open at day
7 in 65% of neonates born < 28 weeks’ gestation [1] and
in 80% at 24-25 weeks [2]. Haemodynamically significant
PDA has been associated with respiratory morbidity in-
cluding: pulmonary haemorrhage (PH), gastrointestinal
and neurological morbidity [3], chronic lung disease
(CLD) [4], necrotising enterocolitis (NEC) [5], intraven-
tricular haemorrhage (IVH) [6] and retinopathy of
prematurity (ROP) [7]. Failure of PDA closure has been
associated with increased mortality [8].
When this study was conceived (2011), there was no
consensus regarding neonatal PDA management [9].
There were three main approaches. Firstly, conservative:
careful ventilation, fluid administration and possibly di-
uretics. Secondly, pharmacological closure: cyclooxygen-
ase inhibitors (COXi)/non-steroidal anti-inflammatory
drugs (NSAID); Indomethacin or Ibuprofen. There was
debate about treatment timing and dosages, with differ-
ent strategies supported by the medical literature. If
medical treatment failed, or was contraindicated surgical
ligation was an option. By 2012, use of high dose
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paracetamol [10] and interventional PDA catheter occlu-
sion (PDACO) [11] was reported, but neither routinely
used in UK neonatal practice.
In 2012 there was limited UK data regarding neonatal
PDA ligation (PDAL). Retrospective studies [12–14] re-
ported PDAL was well tolerated with good initial sur-
vival rates; but higher death rates by 1 year of age.
Survivors had high rates of CLD and neuro-disability,
thought to be complications of prematurity rather than
cardiac surgery. An East of England study [14] estimated
national demand for PDAL using the Epicure 2 data set
[15], calculating that 133 infants born < 26 weeks gesta-
tion would require PDAL annually.
The study aimed to review UK practice of PDAL in
preterm neonates to help inform clinicians which neo-
nates might benefit from PDA ligation; highlighting pro-




A questionnaire (Additional file 1) was sent to all clini-
cians reporting an infant undergoing PDAL (between 1st
Sept 2012 and 30th Sept 2013) through the BPSU “or-
ange card reporting system”, distributed to UK and ROI
consultant paediatricians.
Eligible infants were born < 37 weeks’ gestation, under-
went PDAL before discharge home, with no other car-
diac abnormality. Data included: demographics; pre-
operative medical management; clinical status at PDAL;
and post-operative complications, including mortality.
Missing data, discrepancies and duplicate cases were
clarified through contact with reporting clinicians and
the CTC (cardiothoracic centre).
Ethics
Application was made to BPSU in 2011 with permission
to proceed in September 2012. Funding was through the
Sir Peter Tizard Bursary (held by Dr. Lee). Study ethics
approval was granted by NRES Committee - East Mid-
lands - Derby (Reference: ECC 3-02(FT6)/2012. In-
formed consent from study participants (written or
verbal) for use of routinely collected, then anonymized
data was not necessary as per BPSU agreement with the
national Confidentiality Advisory Group and Health Re-
search Authority.
Data analysis
Data were transferred into the statistical package Stata v15
(Stata Corp., College Station, Tx) for analysis. Categorical
variables were tabulated as frequencies and percentages,
missing data was itemised as a separate category. Continu-
ous variables non-normally distributed were summarised
using median, range and interquartile range. Chi-squared
and Kruskal-Wallis tests were used to assess variations in
outcome between patient groups defined by their gesta-
tional age and weight, at birth and at PDAL. Logistic re-
gression was used to calculate odds ratios for procedure
complications and death according to sex, gestational age
at birth and PDAL, weight at birth and PDAL, and the
type of closure procedure. P-values of < 0.05 were taken to
indicate statistical significance. Results were not adjusted
for multiple hypothesis testing; instead, we chose to
present 95% confidence intervals and p-values to allow the
reader to judge the evidence for themselves. Using UK
birth registration data [16–18] we determined births over
the study period to calculate the incidence of PDAL per
10,000 live births.
Results
Between 1st Sept 2012 to 30th Sept 2013, the BPSU re-
ceived 528 notifications of neonatal PDAL. Only one re-
sponse was received from ROI, therefore we concentrated
on UK data. After identifying duplicate notifications, 263
babies were included (Fig. 1).
Incidence
There were 856,794 UK livebirth registrations over the
study; the incidence of PDAL was 3.07 per 10,000 births.
Demographics
Of the 263 babies undergoing PDAL, 231 (88%) were
born extremely preterm (< 28 weeks gestation), 60% were
male. Two hundred nineteen of the 263 (83%) were ex-
tremely low birth weight (≤ 999 g) (Table 1).
Pre-surgery investigations
Of the 263 infants, 229 (87.1%) had their PDA diagnosed
clinically and confirmed by echocardiography (echo) in
NICU. Thirty-one (11.8%) PDA’s diagnosed by echo
were not suspected clinically based upon answers to the
questionnaire (Additional file 1), however this may po-
tentially reflect clinician error in reporting. In 3 cases
(1.1%) data was not provided. Eight (3%) infants were re-
ported to have their diagnostic echo in the receiving
CTC.
Pre-surgery clinical features
Common reasons for PDAL were haemodynamic signifi-
cance (n = 231, 87.8%), inability to wean respiratory sup-
port (n = 220, 84%) and cardiovascular instability (n = 81,
31%). Some infants had multiple reasons documented
(Table 2). In this study, haemodynamic significance was
not based on any pre-defined criteria or measurements
and left to the discretion of the reporting clinicians.
Extremely preterm and lower birth weight infants were
more likely to be referred for inability to wean respira-
tory support, p = 0.010 and p = 0.042 respectively.
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Moderately preterm infants were referred because of
poor growth (p < 0.001) (Table 2).
Pre-surgery medical management
One hundred and seventy three (65.7%) of the cohort re-
ceived medical treatment before referral. The majority
(n = 143, 82.6%) received targeted therapy, 3 infants had
prophylactic treatment. In 27 cases (15.6%), there was
insufficient information. Ibuprofen was most frequently
used (n = 148, 85.6%) with 11 (6.4%) receiving Indometh-
acin. Seven infants received both drugs. In 7 cases there
was no information. Almost half of treated babies (n =
83, 48%) received one course of Ibuprofen; 42% (n = 73)
received 2 courses, and one received 3 courses.
Treatment was completed in 122 (70.5%) cases. The
commonest reasons for discontinuing treatment were
deranged renal function (35.5%, n = 11) and suspected
sepsis (22.6%, n = 7). Seventy four (28.1%) babies were
not treated medically, of these 56 (75.7%) had several
reasons documented, with renal impairment being the
most frequent (24.3%) (Table 3).
Morbidity pre- PDAL
Neurology
Overall 106 (40.3%) babies had IVH and 13 (4.9%) of the
whole cohort had parenchymal involvement. Eighteen
(6.8%) had documented ROP pre-surgery. Unsurprisingly,
Fig. 1 Case identification
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extremely preterm infants were more likely to have IVH
prior to surgery (p = 0.015).
Respiratory
Two hundred and one (76.4%) infants remained mech-
anically ventilated pre-PDAL, with 124 (61.7%) having
an oxygen requirement > 40%. Thirty-eight (14.4%) were
receiving CPAP, with 7 (18.4%) having an oxygen re-
quirement > 40%, consistent with significant comprom-
ise. PH was reported in 30 (11.4%) babies.
Cardiovascular
Inotropes were being administered to 26 (9.9%) infants,
and fluid restriction (based on local practice) was part of
the medical management in 102 (38.8%) infants at
PDAL. There were no significant differences by gestation
or birth weight.
Nutrition
NEC was confirmed radiologically in 70 (26.7%) infants
pre-PDAL. Almost half the babies (n = 125, 47.5%) were
on full feeds, 10 (3.8%) on full parenteral nutrition (PN),
with 77 (29.2%) receiving some feeds and PN at referral.
In 51 cases, no data was provided. The more premature
and lower birth weight infants were more likely to be re-
ceiving PN at the time of surgery.
Referral pathway
Of the 263 infants referred for PDAL, 199 (75.7%) re-
quired ambulance transfer to a CTC. Of these, 129
(64.8%) had been discussed with one CTC and 25
(12.5%) with two or three centres to arrange PDAL. No
information was available for 45 (22.5%) babies. Of the
whole cohort, 59 (22.4%) babies were in a NICU co-
located with a CTC. In 5 cases, data was unavailable.
The interval between referral and PDAL was median 6
(0-42, IQR 3-9) days. Distance travelled was a median of
15 (0 – 123, IQR 2-30) miles, longest distances were in
Scotland.
Surgical characteristics
Surgery was performed at median age of 33 (9-260, IQR
24-48) days and median weight 1010 (500-4000, IQR
845.5-1410) grams. At PDAL, 133 (50.6%) babies had a
corrected age between 28 and 31 + 6 weeks, and 113
(43%) were < 1 kg. Of the 199 patients transferred to a
CTC, 42.2% were classified as a day case procedure. This






Extreme Preterm (< 28 weeks) 231 (87.8)
Very Preterm (28 + 0 - 31 + 6) 25 (9.5)
Moderately Preterm (32 + 0 - 36 + 6) 7 (2.7)
Birth Weight
Extremely low (≤ 999 g) 219 (83.3)
Very low (1000 – 1499 g) 29 (11.0)
Low (1500-2499 g) 6 (2.3)





Asian or Asian British 23 (8.8)
Black or British Black 28 (10.7)
Chinese or Other 6 (2.3)
Unknown 29 (11.0)
aNumbers do not total 100% due to rounding
Table 2 Decision to refer for surgery based on gestational age at birth, with P values
Reason for decision to refer for
surgery







Extremely preterm (n = 231) Very preterm (n = 25) Moderately preterm (n = 7)
Inability to wean respiratory support 199 (86.2) 17 (68.0) 4 (57.1) 0.010
Haemodynamically Significant 203 (87.9) 18 (72.0) 6 (85.7) 0.090
Cardiovascular instability 73 (31.6) 6 (24.0) 2 (28.6) 0.730
Poor growth 48 (20.8) 11 (44.0) 5 (71.4) < 0.001
Contra-indication of medical therapy 44 (19.1) 3 (12.0) 0 (0) 0.312
Othera 31 (13.4) 3 (12.0) 3 (42.9) 0.083
a Other reasons (n = 37) included: Unable to complete medical treatment (n = 12), NEC (n = 8), PH (n = 4), feeding difficulty (n = 2), duct thought not to be related
to prematurity (n = 1), evolving aortic stenosis (n = 1), RSV negative bronchiolitis (n = 1), pulmonary hypoplasia (n = 1), congestive cardiac failure (n = 1), thrombus
in aorta (n = 1), chromosome disorder (mosaic trisomy 14) (n = 1). 4 questionnaires specified “other” but no further explanation was documented
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could mean admission and discharge on same day, or
may include one overnight stay.
Surgical procedure
Open ligation was performed in 237 (90%) neonates, in-
cluding one following an unsuccessful PDACO. PDACO
was successfully performed in 9 (3.4%) infants with me-
dian weight 2060 (558 – 3388, IQR 1900 - 2620) grams.
Method of PDA closure was not documented in 17
(6.5%) cases. All procedures were conducted in a CTC,
with 60.8% undertaken in theatre and 29.7% performed
on a co-located NICU. In 9.5% of cases this information
was unavailable. Procedures were conducted in 13 CTCs,
the median number was 13 (4-50, IQR 6-35) (Fig. 2).
Length of intubation post-procedure
Perioperative ventilation data was reported for 192 of
the 283 (73%) babies in the cohort and showed median
time from PDAL to extubation of 5 days (0-46, IQR 2-
12). Babies who had always been intubated pre-PDAL
were extubated after a median of 7 days (1-46, IQR 1-
41). Those electively intubated for the procedure were
extubated after median of 2 days (0-7, IQR 1-5). Ex-
tremely preterm infants took longer to extubate (p <
0.001). There was no significant difference in time to
extubation between neonates undergoing open ligation
compared to PDACO.
Post-operative complications
Post-operative complications occurred in 54 (20.5%)
cases, most frequent were: pneumothorax (n = 25, 9.5%),
vocal cord palsy (n = 6, 2.3%), wound infection (n = 6,
2.3%) and chylothorax (n = 2, 0.8%) (See additional file 2
for full list). Two infants (0.8%) died on the second post-
operative day, in neither was death directly attributed to
PDAL. There were no significant differences in compli-
cation rates by sub-group analysis (Additional file 3).
We did not collect post-procedure information from the
CTC regarding post-PDAL syndrome including: haemo-
dynamic instability, inotrope use, blood product admin-
istration, ventilator instability or oxygen requirements.
Table 3 Reasons for not using NSAID pre-surgery
n (%)





> 21 days old when decision to treat made 13 (17.6)
Abdominal Concerns
(bilious aspirate/concern re. NEC/Feed intolerance)
9 (12.2)
Pulmonary Haemorrhage 2 (2.7)
Spontaneous Gut Perforation 2 (2.7)
Other 6 (8.1)
Other reasons (n = 6) included: not indicated, limb ischemia, exomphalos
major, pericardial effusion, minimal support needed, expectation PDA would
close without pharmacological treatment
Fig. 2 Bar graph illustrating number of PDA surgeries undertaken by cardiothoracic centre
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Morbidity post- surgery
Of the 263 infants, 132 (50.2%) developed CLD, defined
as need for supplementary oxygen at 36 weeks corrected,
85 (64.4%) received diuretics and 29 (22%) post-natal
steroids. Only 18 (13.6%) required no additional medical
treatments. Extremely low birth weight babies were
more likely to require medical treatment (steroids p =
0.041 and diuretics p = 0.035). 32 (12.2%) infants re-
quired laser treatment for ROP following ligation. 12
(4.6%) infants developed further episodes of NEC requir-
ing surgery. No further episodes of PH were docu-
mented. There were no significant differences in post-
operative co-morbidities by gestational age.
Mortality
There were 17 (6.5%) deaths. For 16 patients the interval
between PDAL and death was available, median 33 (2-
239, IQR 10-89) days. Eight infants died within 30 days
of surgery giving an overall 30-day mortality of 3%.
There were no significant differences in mortality rates
by sub-group analysis (Additional file 4).
Discussion
This was the first UK wide study to investigate the man-
agement of preterm infants undergoing PDAL. Our in-
clusion criteria were designed to capture neonates failing
medical management or where it was contraindicated. In
2012-2013, there was no consensus about optimal man-
agement of PDA, timing of medical treatment or when
PDA ligation should be considered. These controversies
are unchanged in 2021. We believe our study provides
important information about PDAL, which is still rele-
vant today. The study highlights the characteristics of
babies referred, and provides outcome information about
morbidity and survival.
In our study, PDA ligation occurred in 3.07 per 100,
000 live births. We note that the prevalence of PDAL in
premature babies will be higher, but did not have access
to preterm denominator data in order to calculate
ligation rates accurately in this population. We also did
not have contemporaneous access to the NICOR (Na-
tional Institute for Cardiovascular Outcomes Research)
database, which provides information about all UK PDA
closures, not just in the neonatal population [19]. Com-
parisons with NICOR data are difficult, as our study ran
over 2 NICOR reporting years, 2012/13 and 2013/14.
Their dataset classifies neonates as < 30 days and an in-
fant as 31 days to 1 year of age [20]. Over half of our co-
hort might be classified as infants, with a median age of
33 days at PDAL, making it almost impossible to cross-
reference numbers. Their data identified only a small
number of PDACO, consistent with our observations.
Subsequent NICOR data up to 2016 (Additional file 5)
suggests fewer neonates are undergoing PDA closure,
but it will be difficult to apply this to the preterm popu-
lation because of their classification criteria.
Our study again highlights that a higher proportion of
extremely preterm males with extremely low birth
weight, and ethnically classified as white, require PDAL;
correlating with other published series [21–24]. The ma-
jority of infants in this study were reliant on mechanical
ventilation prior to surgery, with 62% needing > 40%
oxygen, consistent with significant respiratory comprom-
ise. It is a limitation of our study that we did not more
accurately define haemodynamic significance in terms of
PDA diameter, left atrium: aorta ratios or blood flow
patterns. Many of the infants required ambulance trans-
fer with the additional resources and challenges this
poses. Some CTCs performed more surgical procedures
than others, which may simply reflect the geographical
population they serve, but could signify different referral
practices for surgical intervention. Such variations are
likely to continue until there is a greater consensus re-
garding management of the neonatal PDA.
The overall mortality rate in our study was 6.5%, with
a 30-day mortality rate of 3%. It is reassuring that PDA
surgery appears a relatively safe procedure in this chal-
lenging patient population. Complication rates were re-
corded as 20.5%, most such as pneumothoraces and
wound infections were easily treated. Vocal cord palsies
and chylothoraces should be considered more chronic
complications.
The most common pre-surgical co-morbidities were
IVH and NEC, in keeping with published literature [25,
26]. It has been suggested that the incidence of CLD in-
creases following PDA surgery [4, 12–14, 25, 26]. In our
cohort, 50% of babies had CLD, but in reality, this will
be an underestimate as 28% had either not reached 36
weeks corrected age or had died by study close. As this
was a nationwide questionnaire based study, we could
not identify case-control groups to compare whether
rates of CLD and other complications were statistically
higher following surgical closure, which is a limitation of
our observational study.
It is important to consider whether this study is rele-
vant to neonatologists in 2021. In 2014, Heuchan et al.
[27], reported that the optimal management of the PDA
in premature infants remained controversial, as did San-
kar et al. [28] in 2019. Over the 7 years since this study
ended there have been many advances in neonatal care:
including the wider use of paracetamol [29]; different
evidence-based approaches to the management of re-
spiratory distress syndrome [30]; and new techniques for
less invasive surfactant administration (LISA) [31] all of
which may have contributed to fewer neonates and in-
fants requiring PDA closure, as suggested by the NICOR
data. Despite these advances, PDA management remains
controversial. There is still no consensus on whether to,
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or when to treat pharmacologically. Many clinicians now
accept a PDA, treating fewer medically and limiting
PDAL to babies with worsening respiratory failure.
There are ongoing worldwide trials assessing the benefits
of early versus no pharmacological treatment: the
OSCAR Study [32], Beneductus Trial [33] and EPAR
Trial [34]. The recent international PDA-TOLERATE
pilot exploratory trial [35] with 202 infants, showed no
difference in PDA ligation rates between the control and
treatment groups. Small numbers of neonates will con-
tinue to require PDA closure with increasing evidence
that transcatheter closure is being safely used [36].
Conclusion
Our study provides important information on ap-
proaches to PDA management across the UK in 2012/
2013. Extremely preterm and extremely low birth weight
male infants were more likely to undergo PDAL due to
failed pharmacological treatment and / or ongoing inva-
sive ventilation requirement. This study suggests that
PDAL has a high survival rate (93.5%), with the majority
of patients (80%) suffering no complications. It also sug-
gests a potential link between PDA surgery and CLD
needing on-going treatment.
This study confirmed there was variation in medical
management used prior to referral for PDAL. This vari-
ation persists in 2021 with ongoing debate regarding ap-
propriate management strategies. If our BPSU study was
conducted again today, we might find more neonates
had been treated medically with Paracetamol, and of
those referred for PDA closure, a greater proportion
might undergo catheter occlusion.
This study should stimulate the neonatal community
to consider standardising the medical and surgical man-
agement of neonatal PDA. Getting it right first time
(GIRFT) neonatal network reviews should help to iden-
tify best practice and identify outliers.
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